ATO and venetoclax synergistically induces the apoptosis of NPM1-mutated OCI-AML3 cells in vitro and showed anti-leukemia activity in two relapsed and/or refractory (R/R) NPM1-mutated AML patients (47). Here, RUNX2 is linked to acute myeloid leukemia.